跳至主要内容
临床试验/NCT01089205
NCT01089205已完成1 期

An Open-Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Metformin Hydrochloride Extended Release 750 mg Tablets (Test Formulation, Torrent Pharmaceuticals Ltd., India) Versus Glucophage XR® 750 mg Tablet (Reference Formulation, Bristol-Myers Squibb Company, USA) in Healthy Volunteers Under Fed Conditions.

Torrent Pharmaceuticals Limited0 个研究点开始时间: 2010年3月18日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成

研究概览

简要总结

Objective:

To study Bioequivalence of Metformin Hydrochloride Extended Release 750 mg Tablets (Test formulation, Torrent Pharmaceuticals Ltd., India) Versus Glucophage XR® 750 mg Tablet (Reference formulation, Bristol-Myers Squibb company, USA) in Healthy volunteers under Fed Conditions.

Study Design:

An Open-Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Volunteers must meet all of the following criteria in order to be included in the study:
  • Age: 18 - 45 years.
  • Volunteer with BMI of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight.
  • Healthy and willing to participate in the study.
  • Volunteer willing to adhere to the protocol requirements and to provide written informed consent.
  • Non-smokers or smoker who smokes less than 10 cigarettes a day.

排除标准

  • The volunteers will be excluded from the study based on the following criteria:
  • Clinically relevant abnormalities in the results of the laboratory screening evaluation.
  • Clinically significant abnormal ECG or Chest X-ray.
  • Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg and diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.
  • Pulse rate less than 50/minute or more than 100/minute.
  • Oral temperature less than 95°F or more than 98.6°F.
  • Respiratory rate less than 12/minute or more than 20/minute
  • Addiction to alcohol or history of any drug abuse within the past 2 years.
  • Recent History of kidney or liver dysfunction.
  • History of allergy to the test drug or any drug chemically similar to the drug under investigation.
  • Administration/ Intake of prescription or OTC medication for two weeks before the study.
  • Patients suffering from any chronic illness such as arthritis, asthma etc.
  • HIV, HCV, HBsAg positive volunteers.
  • Opioids, tetra hydrocannabinoids, amphetamine, barbiturates, benzodiazepine, Cocaine positive volunteers based on urine test.
  • Volunteers suffering from any psychiatric (acute or chronic) illness requiring medications.
  • Administration of any investigational products in the period 0 to 3 months before entry to the study.
  • Intake of barbiturates or any enzyme-inducing drug in last three months.
  • History of significant blood loss due to any reason, including blood donation in the past 12 weeks. The total blood loss in last 3 months including for this study will not exceed 350ml.
  • Existence of any surgical or medical condition, which, in the judgement of the Chief Investigator and/or clinical investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug or likely to compromise the safety of Volunteers.
  • Inability to communicate or co-operate due to language problem, poor mental development or impaired cerebral function.

研究组 & 干预措施

Torrent's Metformin tablets 750 mg

Experimental

干预措施: Metformin (Drug)

Glucophage XR® of Bristol- Myers Squibb Company, USA

Active Comparator

干预措施: Metformin (Drug)

研究者

申办方类型
Industry

相似试验